To read the full story
Related Article
- JPMA Sacks Hasegawa as Vice President after Business Improvement Order
July 3, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
September 19, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
- Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
- Takeda Extended 3.7 Billion Yen in CASE-J-Linked Grants to Kyoto Univ., 2 Entities; “No COI” Says Pres. Hasegawa
March 4, 2014
- Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
- Japanese Cardiologist Raises Statistical Concerns over CASE-J Study in US Journal
February 28, 2014
ORGANIZATION
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
- PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
December 26, 2024
- Off-Year Revisions Need Careful Assessments and Discussions: Chuikyo JMA Rep
December 20, 2024
- JPMA to Continue Seeking Repeal of Off-Year Revisions: Exec
December 20, 2024
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…